DHG Pharmaceutical Joint Stock Company (DHG.VN) Stock

DHG.VN logo

DHG Pharmaceutical Joint Stock Company

DHG.VNVietnam
Healthcare

Company profile

DHG Pharmaceutical Joint Stock reported revenue of 5.27 trillion VND for fiscal year 2025, up 7.8% from fiscal year 2024, and net income of 824.78 billion VND. That is a net profit margin of 15.7% for fiscal year 2025. In Q2 2026 (the quarter ended June 30, 2026) revenue was 1.36 trillion VND, up 15.1% from a year before. In Q2 2026 it reported net income of 298.67 billion VND, against net income of 236.89 billion VND a year earlier. Our analysis of its filings shows revenue growing from 5.02 trillion VND in fiscal year 2023 to 5.27 trillion VND in fiscal year 2025, 2.5% a year on average. DHG Pharmaceutical Joint Stock reports about 2,812 full-time employees.

What stands out

  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About DHG Pharmaceutical Joint Stock Company

DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, dermatology, and beauty care products. It also manufactures and trades in health food, dietary and consumer health supplements, and pharmaceuticals cosmetic products. It also exports its products. DHG Pharmaceutical Joint Stock Company was founded in 1974 and is headquartered in Can Tho, Vietnam. DHG Pharmaceutical Joint Stock Company is a subsidiary of Taisho Pharmaceutical Co., Ltd.

Leadership

  • Huan Buu Ho — Chief Accountant, 45
  • Diep Ngoc Nguyen — Deputy General Director, 57
  • Tomoyuki Kawata — Deputy General Director, 59
  • Hung Thanh Ta — Information Technology Director
  • Chuong Ngoc Nguyen — Production Director

How much revenue does DHG Pharmaceutical Joint Stock make?

DHG Pharmaceutical Joint Stock reported 5.27 trillion VND in revenue for fiscal year 2025, up 7.8% from 4.88 trillion VND in fiscal year 2024. In Q2 2026 revenue was 1.36 trillion VND.

What companies are similar to DHG Pharmaceutical Joint Stock?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (DBD.VN), Cuu Long Pharmaceutical Joint Stock Company (DCL.VN), F.i.t Group Joint Stock Company (FIT.VN).

How has DHG Pharmaceutical Joint Stock's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 4.00 trillion VND; FY2022, 4.68 trillion VND; FY2023, 5.02 trillion VND; FY2024, 4.88 trillion VND; FY2025, 5.27 trillion VND.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees2,812
HeadquartersCan Tho, Vietnam
ExchangeHOSE
TimezoneAsia/Bangkok (ICT)

Contact & Links

Address
288 Bis Nguyen Van Cu Street, Can Tho
Phone
84 292 3891 433
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “DHG Pharmaceutical Joint Stock Company (DHG.VN)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/DHG.VN

LinkedInLinkedInXXYouTubeYouTube